Femasys Inc. Common Stock
FEMYStock
$3.05−80.86%52W
Market Cap$9.21M
P/E—
Div yield—
Beta-2.19
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-80.88%
Price vs S&P 500 (4W)-7.63%
VGM Score47.30
Market Capitalization$9.21M
Earnings Surprise History
Q2 25-3.00est. -3.67
Q3 25-2.00est. -2.65
Q4 25-0.20est. -1.78
Q1 26-1.20est. -0.09
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.11
4.10
4.10
4.11
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FEMYFemasys Inc. Common Stock | C | B | F | $3.05 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
Femasys develops minimally invasive medical devices for women's healthcare, offering office-based solutions for infertility treatment, contraception, and diagnostic procedures. Its product portfolio includes FemaSeed for intratubal insemination, FemVue for fallopian tube assessment, FemBloc for permanent contraception (in development), FemCerv for cervical cancer diagnosis, and FemCath and FemChec. The company generates revenue primarily from the United States market with additional international sales.